DocGo Reports Q1 2026 Earnings with Revenue Growth and Strategic Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Source: seekingalpha
- Revenue Growth: DocGo reported $75.6 million in revenue for Q1 2026, despite an adjusted EBITDA loss of $10.2 million, indicating strong revenue performance while still facing profitability challenges.
- Upgraded 2026 Revenue Guidance: The company raised its 2026 revenue guidance from $290 million to $310 million to a new range of $300 million to $315 million, reflecting optimism about SteadyMD's growth while keeping adjusted EBITDA loss guidance unchanged, demonstrating management's cautious outlook.
- SteadyMD Performance: SteadyMD generated over $9 million in revenue during Q1, completing approximately 1.1 million visits and lab orders, a 38% increase year-over-year, with a projected 75% growth in 2026, highlighting the company's expansion potential in home healthcare services.
- Cash Flow Pressure: As of March 31, 2026, DocGo's cash and cash equivalents totaled $59.9 million, down from $68.3 million at the end of 2025, with expected short-term cash flow pressures, as management plans to return to profitability in the second half of the year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DCGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DCGO
Wall Street analysts forecast DCGO stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.602
Low
1.50
Averages
3.13
High
4.00
Current: 0.602
Low
1.50
Averages
3.13
High
4.00
About DCGO
DocGo Inc. is a mobile healthcare services company that uses dispatch and communication technology to help provide mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations and healthcare transportation in major metropolitan cities in the United States and the United Kingdom. The Company’s offerings also include mobile phlebotomy lab services, which is engaged in addressing critical gaps in diagnostic care for underserved populations. The Mobile Health Services include a variety of healthcare services performed at homes, offices and other locations and event services, such as on-site healthcare support at sporting events and concerts. The Transportation Services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DocGo Reports Q1 2026 Earnings with Revenue Growth and Strategic Outlook
- Revenue Growth: DocGo reported $75.6 million in revenue for Q1 2026, despite an adjusted EBITDA loss of $10.2 million, indicating strong revenue performance while still facing profitability challenges.
- Upgraded 2026 Revenue Guidance: The company raised its 2026 revenue guidance from $290 million to $310 million to a new range of $300 million to $315 million, reflecting optimism about SteadyMD's growth while keeping adjusted EBITDA loss guidance unchanged, demonstrating management's cautious outlook.
- SteadyMD Performance: SteadyMD generated over $9 million in revenue during Q1, completing approximately 1.1 million visits and lab orders, a 38% increase year-over-year, with a projected 75% growth in 2026, highlighting the company's expansion potential in home healthcare services.
- Cash Flow Pressure: As of March 31, 2026, DocGo's cash and cash equivalents totaled $59.9 million, down from $68.3 million at the end of 2025, with expected short-term cash flow pressures, as management plans to return to profitability in the second half of the year.
See More
DocGo CEO to Present at 21st Annual Needham Conference
- Presentation Schedule: DocGo's CEO Lee Bienstock is set to deliver a company presentation at the 21st Annual Needham Technology, Media, & Consumer Conference on May 14 from 11:45 AM to 12:25 PM ET, showcasing DocGo's leadership in medical transportation and mobile health services.
- 1x1 Meeting Participation: Bienstock will also engage in 1x1 meetings at the event, enhancing communication with investors and increasing market awareness of DocGo's innovative healthcare solutions.
- Innovative Healthcare Platform: DocGo is reshaping the traditional healthcare system with its innovative care delivery platform that includes mobile health services, remote patient monitoring, and a 50-state virtual care network, significantly improving patient care quality and accessibility.
- Efficiency Through Technology: The proprietary technology and dedicated team of certified health professionals at DocGo elevate patient care quality while driving business efficiencies for healthcare facilities, hospital networks, and insurance providers, thus transforming the healthcare landscape.
See More
DocGo to Release Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: DocGo will release its financial results for Q1 2026 after market close on May 11, 2026, highlighting the company's ongoing growth potential in medical transportation and mobile health services.
- Conference Call Details: Management will host a conference call at 5:00 p.m. ET on the same day, providing a direct interaction opportunity with investors, expected to discuss financial results and future strategies, enhancing transparency and investor confidence.
- Innovative Healthcare Platform: DocGo is reshaping the traditional healthcare system with its innovative care delivery platform, offering diverse services including mobile health and remote patient monitoring, aimed at improving care quality and accessibility for patients.
- Technology-Driven Efficiency Gains: The company's proprietary technology and dedicated team of certified health professionals elevate patient care quality while driving business efficiencies for healthcare facilities and insurance providers, enhancing DocGo's competitiveness in the rapidly evolving healthcare market.
See More
DocGo Recognized as One of the 2026 World's Most Ethical Companies
- Ethical Recognition: DocGo Inc. has been honored by Ethisphere as one of the 2026 World's Most Ethical Companies, highlighting the company's exceptional performance in ethics and compliance within the healthcare sector, thereby enhancing its reputation and competitive edge in the industry.
- Industry Leadership: As one of only four honorees in the healthcare providers category, DocGo's recognition among 138 awardees underscores its unique position and further solidifies its leadership in the medical technology field.
- Governance and Compliance Strengthening: Chief Compliance Officer Stephen Sugrue emphasized that DocGo's efforts in governance, risk, and compliance have made ethical behavior central to daily decision-making, improving overall operational efficiency and employee satisfaction.
- Commitment to Continuous Improvement: CEO Lee Bienstock stated that the company will continue to focus on strong governance and transparency to ensure that ethics and integrity remain paramount in the rapidly evolving healthcare landscape, thus driving long-term business success.
See More
DocGo Inc. Reports Q4 2025 Earnings Highlights
- Revenue Performance: DocGo reported $74.9 million in Q4 2025 revenue, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects, highlighting the challenges and opportunities in the company's transformation process.
- EBITDA Loss Improvement: The adjusted EBITDA loss was $11.6 million, with management projecting a reduction to $5 million to $10 million in 2026, reflecting positive progress in cost control and operational efficiency.
- SteadyMD's Strong Performance: SteadyMD exceeded $8 million in revenue for the first time in Q4, driving overall revenue growth and expected to continue as a key growth driver for the company in 2026.
- Exploration of Strategic Alternatives: DocGo has initiated a process to explore various strategic alternatives aimed at maximizing shareholder value, demonstrating management's proactive approach to future developments and sensitivity to market changes.
See More
DocGo (DCGO) Q4 2025 Earnings Call Transcript
See More
DocGo Reports Q1 2026 Earnings with Revenue Growth and Strategic Outlook
- Revenue Growth: DocGo reported $75.6 million in revenue for Q1 2026, despite an adjusted EBITDA loss of $10.2 million, indicating strong revenue performance while still facing profitability challenges.
- Upgraded 2026 Revenue Guidance: The company raised its 2026 revenue guidance from $290 million to $310 million to a new range of $300 million to $315 million, reflecting optimism about SteadyMD's growth while keeping adjusted EBITDA loss guidance unchanged, demonstrating management's cautious outlook.
- SteadyMD Performance: SteadyMD generated over $9 million in revenue during Q1, completing approximately 1.1 million visits and lab orders, a 38% increase year-over-year, with a projected 75% growth in 2026, highlighting the company's expansion potential in home healthcare services.
- Cash Flow Pressure: As of March 31, 2026, DocGo's cash and cash equivalents totaled $59.9 million, down from $68.3 million at the end of 2025, with expected short-term cash flow pressures, as management plans to return to profitability in the second half of the year.
See More
DocGo CEO to Present at 21st Annual Needham Conference
- Presentation Schedule: DocGo's CEO Lee Bienstock is set to deliver a company presentation at the 21st Annual Needham Technology, Media, & Consumer Conference on May 14 from 11:45 AM to 12:25 PM ET, showcasing DocGo's leadership in medical transportation and mobile health services.
- 1x1 Meeting Participation: Bienstock will also engage in 1x1 meetings at the event, enhancing communication with investors and increasing market awareness of DocGo's innovative healthcare solutions.
- Innovative Healthcare Platform: DocGo is reshaping the traditional healthcare system with its innovative care delivery platform that includes mobile health services, remote patient monitoring, and a 50-state virtual care network, significantly improving patient care quality and accessibility.
- Efficiency Through Technology: The proprietary technology and dedicated team of certified health professionals at DocGo elevate patient care quality while driving business efficiencies for healthcare facilities, hospital networks, and insurance providers, thus transforming the healthcare landscape.
See More
DocGo to Release Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: DocGo will release its financial results for Q1 2026 after market close on May 11, 2026, highlighting the company's ongoing growth potential in medical transportation and mobile health services.
- Conference Call Details: Management will host a conference call at 5:00 p.m. ET on the same day, providing a direct interaction opportunity with investors, expected to discuss financial results and future strategies, enhancing transparency and investor confidence.
- Innovative Healthcare Platform: DocGo is reshaping the traditional healthcare system with its innovative care delivery platform, offering diverse services including mobile health and remote patient monitoring, aimed at improving care quality and accessibility for patients.
- Technology-Driven Efficiency Gains: The company's proprietary technology and dedicated team of certified health professionals elevate patient care quality while driving business efficiencies for healthcare facilities and insurance providers, enhancing DocGo's competitiveness in the rapidly evolving healthcare market.
See More
DocGo Recognized as One of the 2026 World's Most Ethical Companies
- Ethical Recognition: DocGo Inc. has been honored by Ethisphere as one of the 2026 World's Most Ethical Companies, highlighting the company's exceptional performance in ethics and compliance within the healthcare sector, thereby enhancing its reputation and competitive edge in the industry.
- Industry Leadership: As one of only four honorees in the healthcare providers category, DocGo's recognition among 138 awardees underscores its unique position and further solidifies its leadership in the medical technology field.
- Governance and Compliance Strengthening: Chief Compliance Officer Stephen Sugrue emphasized that DocGo's efforts in governance, risk, and compliance have made ethical behavior central to daily decision-making, improving overall operational efficiency and employee satisfaction.
- Commitment to Continuous Improvement: CEO Lee Bienstock stated that the company will continue to focus on strong governance and transparency to ensure that ethics and integrity remain paramount in the rapidly evolving healthcare landscape, thus driving long-term business success.
See More
DocGo Inc. Reports Q4 2025 Earnings Highlights
- Revenue Performance: DocGo reported $74.9 million in Q4 2025 revenue, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects, highlighting the challenges and opportunities in the company's transformation process.
- EBITDA Loss Improvement: The adjusted EBITDA loss was $11.6 million, with management projecting a reduction to $5 million to $10 million in 2026, reflecting positive progress in cost control and operational efficiency.
- SteadyMD's Strong Performance: SteadyMD exceeded $8 million in revenue for the first time in Q4, driving overall revenue growth and expected to continue as a key growth driver for the company in 2026.
- Exploration of Strategic Alternatives: DocGo has initiated a process to explore various strategic alternatives aimed at maximizing shareholder value, demonstrating management's proactive approach to future developments and sensitivity to market changes.
See More
DocGo (DCGO) Q4 2025 Earnings Call Transcript
See More
